Transplantation of allogenic bone marrow inacute leukemias and chronic myeloid leukemia


Cite item

Full Text

About the authors

L P Mendeleeva

References

  1. Thomas E. D., Lochte H. L., Lu W. С. et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N. Engl. J. Med. 1957; 257: 491-496.
  2. Fefer A., Einstein А. В., Thomas E. D. Bone-marrow transplantation for hematologic neoplasia in 16 patients with identical twins. Ibid. 1974; 290: 1389-1393.
  3. Thomas E. D., Lochte H. L., Ferrebee J. W. Irradiation of the entire body and marrow transplantation: some observations and comments. Blood 1959; 14: 1-23.
  4. Thomas E. D., Buckner С. D., Banaji M. et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Ibid. 1977;49:511-533.
  5. Fefer A., Thomas E. D. Marrow transplantation in the treatment of acute leukemia. In: Henderson E. S., Lister T. A. Leukemia. Philadelphia: W. B. Saunders Company; 1990. 431-441.
  6. Zander A. R., Keating M., Dicke K. et al. A comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission. J. Clin. Oncol. 1988; 6: 1548-1557.
  7. Forman S. J., Scymidt G. M., Nademanee A. P. et al. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. Ibid. 1991: 9: 1570-1574.
  8. Любимова Л. С., Савченко В. Г., Менделеева Л. П. и др. Эффективность трансплантации аллогенного костного мозга у больных острыми лейкозами в фазе полной ремиссии и у больных хроническим миелолейкозом в хронической фазе. Тер. арх. 1999; 7: 27-32.
  9. McGlave P. В., Haake R. J., Bostrom В. С. et al. Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. Ibid. 1988; 72: 1512-1517.
  10. Young J. W., Papadopoulos E. В., Cunningham I. et al. T-cell- depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Ibid. 1992; 79: 3380-3387.
  11. Appelbaum F. R., Dahlberg S., Thomas E. D. et al. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann. Intern. Med. 1984; 101: 581-588.
  12. Schiller G. L., Nimer S. D., Territo M. С. et al. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J. Clin. Oncol. 1992; 10: 41-46.
  13. Reiffers J., Gaspard M. N., Maraninchi D. et al. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukemia in first remission: A prospective controlled trail. Br. J. Haematol. 1989; 72: 57-63.
  14. Mitus A. J., Miller К. В., Schenkein D. P. et al. Improved survival for patients with acute myelogenous leukemia. J. Clin. Oncol. 1995; 13: 560-569.
  15. Gorin N. C., Labopin M., Fouillard L. et al. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1996; 18: 111-117.
  16. Zittoum R. A., Mandelli F., Willemze R. et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N. Engl. J. Med. 1995; 332: 217-223.
  17. Bostrom В., Brunning R. D., McGlave P. et al. Bone marrow transplantation for acute nonlymphocytic leukemia in first remission: analysis of prognostic factors. Blood. 1985; 65:1191- 1196.
  18. Fagioli F., Bacigalupo A., Frassoni F. et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission: the effect of FAB classification and GVHD prophilaxis. Bone Marrow Transplant. 1994; 13: 247- 252,
  19. Keating S., Suciu S., Witte T. et al. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: An analysis of the EORTC/GIMEMA AML 8A trial. Ibid. 1996; 17:993-1001.
  20. Ferrant A., Labopin M., Frassoni F. et al. Karyotype in acute myeloblasts leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation Study. Blood 1997; 90: 2931-2938.
  21. Appelbaum F. R., Clift R. A., Buckner C. D. et al. Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse. Ibid. 1983; 61: 949-953.
  22. Gale R. P., Horowits M. M., Rees J. K. et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia 1996; 10: 13-19.
  23. Sebban C., Lepage E., Vemant J. P. et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: A comparative study. J. Clin. Oncol. 1994; 12: 2580-2587.
  24. Vey N., Blaise D., Stoppa A. M. et al. Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant. 1994; 14: 383-388.
  25. Chao N. J., Forman S. J., Schmidt G. M. et al. Allogeneic bone marrow transplantation for hihg-risk acute lymphoblastic leukemia during first complete remission. Blood 1991; 78: 1923-1927.
  26. Appelbaum F. R. Allogeneic hematopoietic stem cell transplantation for acute leukemia. Semin. Oncol. 1997; 24: 114-123.
  27. Doney K., Fisher L. D., Appelbaum F. R. et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse and relapse-free survival. Bone Marrow Transplant. 1991; 7: 453-459.
  28. Wingard J. R., Piantadosi S., Santos G. W. et al. Allogeneic bone marrow transplantation for hihg-risk acute lymphoblastic leukemia. J. Clin. Oncol. 1990; 8: 820-830.
  29. Hehlmann R., Heimpel H., Hasford J. et al. Randomised comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by hydroxyurea. Blood 1993; 82: 398-407.
  30. Guilhot F., Chastang C., Michallet M. et al. Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N. Engl. J. Med. 1997; 337: 223-229.
  31. Ohnishi K., Ohno R., Tomonaga M. et al. A randomized trial comparing interferon-a with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86: 906-916.
  32. Hochhaus A., Kantarjian H. M., Sawyers C. L. et al. Glivek (Imatinib Mesylate, STI571) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloid leukemia in late chronic phase. Hematol. J. 2001; 1 (suppi. 1 Abstracts for the 6"' Annual Meeting of the European Haematology Association): abstr. 736.
  33. Fefer A., Cheever M. A., Thomas E. D. et al. Disappearance of Ph'-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N. Engl. J. Med. 1979; 300: 333-337.
  34. Fefer A., Cheever M. A., Greenberg P. D. et al. Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. Ibid. 1982; 306: 63-68.
  35. Thomas E. D., Clift R. A., Fefer A. et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann. Intern. Med. 1986; 104: 155-163.
  36. Clift R. A., Appelbaum F. R., Thomas E. D. et al. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993; 82: 1954-1956.
  37. Cross N., Feng L., Chase A. et al. Competitive polymerase chain reaction to estimate the numbsr of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Ibid : 1929-1936.
  38. Biggs J. C., Szer J., Crilley P. et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Ibid. 1992; 80: 1090-1093.
  39. Clift R. A., Buckner С. D., Thomas E. D. et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Ibid. 1994; 84: 4368-4373.
  40. Devergie A., Reiffers J., Vernant J. P. et al. Long-term follow-up after bone marrow transplantation for chronic myelogenous leukemia: Factors associated with relapse. Bone Marrow Transplant. 1990; 5: 379-386.
  41. Bortin M. M., Horowitz M. M., Rimm A. A. Progress report from the International Bone Marrow Registry. Ibid. 1992; 10: 113-122.
  42. Bauduer F., Delmer A., Blanc M. С. et al. Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with hihg- or intermediate-dose cytosine arabinoside and amcacrine. Leukemia and Lymphoma 1993; 10: 195-200.
  43. Derderian P. M., Kantarjian H. M., Talpaz M. et al. Chronic myelogenous leukemia in the lymphoid blastic stage: Characteristics, treatment response and prognosis. Am. J. Med. 1993; 94: 69-74.
  44. Collins R., Rogers Z., Bennett M. et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: Apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant. 1992; 10: 391-395.
  45. Kolb H-J., Schattenberg A., Goldman J. M. et al. Graft-versusleukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
  46. Mortimer J., Blinder M. A., Schulman S. et al. Relapse of acute leukemia after marrow transplantation: Natural history and results of subsequent therapy. J. Clin. Oncol. 1989; 7: 50-57.
  47. Frassoni F., Barrett A. J., Granena A. et al. Relapse after allogeneic bone marrow transplantation for acute leukemia: A survey by the EBMT of 117 cases. Br. J. Haematol. 1988; 70: 317-320.
  48. Chiang K. Y., Weisdorf D., Daves S. M. et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse. Bone Marrow Transplant. 1996; 17: 39-42.
  49. Lalit K. Leukemia: Management of relapse after allogeneic bone marrow transplantation. J. Clin. Oncol. 1994; 12: 1710- 1717.
  50. Wagner J. E., Vogelsang G. В., Zehnbauer B. A. et al. Relapse of leukemia after bone marrow transplantation: Effect of second myeloablative therapy. Bone Marrow Transplant. 1992; 9: 205-209.
  51. Giralt S., Escudier S., Kantarijan H. et al. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N.Engl. J. Med. 1993; 329: 757-761.
  52. Giralt S., Champlin R. E. et al. Leukemia relapse after allogeneic bone marrow transplantation. Blood 1994; 84: 3603- 3612.
  53. Arcese W., Goldman J. M., Darcangelo E. et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Ibid. 1993; 82: 3211-3219.
  54. Higano С. S., Raskind W. H., Singer J. W. et al. Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic marrow transplantation. Ibid. 1992; 80: 1437-1442.
  55. Kolb H. J., Mittermueller J., Clemm С. et al. Donor leukocyte transfusions for treatment of reccurrent chronic myelogenous leukemia in marrow transplant patients. Ibid. 1990: 76: 2462- 2465.
  56. Fores R., Diez-Martin J. L., Briz M et al. Donor leukocyte infusions for treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996; 17: 439-441.
  57. Savchenko V., Mendeleeva L., Lubimova L. et al. Donor leukocyte infusion (DL1) in the treatment of AML patients relapsed after allogeneic bone marrow transplantation. (Hiddemann W. et al. Acute leukemias V. Experimental approaches and management of refractory diseases). Berlin; 1996. 383-385.
  58. Szer J., Grigg A. P., Phillips G. L. et al. Donor leukocyte infusions after chemotherapy for patients relapsing with acute leukemia following allogeneic BMT. Bone Marrow Transplant. 1993; 11: 109-111.
  59. Барретт А. Ж. Механизмы реакции трансплантат-против-лейкоза. Пробл. гематол. 1997; 4: 5-16.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies